banda transcan 2 2016ul

Title: Biomarkers for diagnosis and prognosis of endometrial carcinoma

Project Coordinator:
Tea LANIŠNIK RIZNER (Slovenia) University of Ljubljana, Ljubljana

 
Project Partners:
Jerzy ADAMSKI (Germany) Helmholtz Zentrum München, Neuherberg
Christoph SCHRÖDER (Germany) Sciomics GmbH, Heidelberg
Andrea ROMANO (The Netherlands) Maastricht University, Maastricht
Andrzej SEMCZUK (Poland) Lublin Medical University, Lublin
Jaak VILO (Estonia) University of Tartu, Tartu


Project Abstract:
Endometrial cancer (EC) is the most frequent gynecological malignancy in the developed world. Optimal treatment of EC depends on early diagnosis and pre-operative stratification to appropriately select the extent of surgery and to plan further therapeutic approaches. Currently, invasive endometrial histology is the gold standard for diagnosis, as there are no valid non-invasive methods available, and patient stratification is based on histopathology and surgical findings. There is a great need for efficient and reliable screening test for asymptomatic women with high risk of EC including Lynch syndrome patients and tamoxifen treated patients. In addition, a prognostic test is needed to stratify pre-operatively EC patients with high risk of progression in need of radical surgery together with adjuvant chemo/ratio therapy from EC patients with good prognosis. In our project we are addressing this lack of non-invasive diagnostic and prognostic biomarkers of EC. We hypothesize that discrete panels of metabolites and proteins are associated with early EC and aggressive EC, where bioinformatics combined with statistical modeling allows development of diagnostic and prognostic models with high sensitivity and specificity. We thus aim to identify diagnostic metabolite and protein biomarker signatures for early detection of cancer in asymptomatic high-risk population and prognostic biomarkers for selection of patients with poor prognosis. So far there has been no published report on using blood metabolomics and proteomics to search for diagnostic and prognostic biomarkers of EC. To accomplish our aims we will employ non-targeted and targeted metabolomics and semi-targeted proteomics approaches. Our biomarker discovery study will include patients with EC, patients with benign uterine pathologies and healthy women. EC patients will be further divided into groups with low risk and high risk for cancer progression and recurrence. Blood metabolome comprising over 850 metabolites will be analyzed by UHPLC/MS, ESI/MS/MS. Blood proteome including 900 different cancer-related proteins will be analyzed in parallel using high content antibody microarrays. These analytical approaches will be combined with bioinformatics/biostatistical analysis to derive diagnostic and prognostic algorithms based on blood metabolites, proteins and clinical data. Diagnostic biomarkers would be instrumental for early diagnosis and development of screening test, while prognostic biomarkers would allow pre-surgical selection of EC patients with poor prognosis and would thus lead to improved treatment outcomes for the high-risk patients. These biomarkers would reduce overtreatment of EC patients with low risk for progression and would also lower concurrent unnecessary burden to these patients as well as treatment associated health-care costs.

 

 

(Project funded under JTC 2016)


TRANSCAN News

Launch of the call: JTC 2021
The new TRANSCAN-3 project consortium is launching the first Joint Transnational Call for proposals, co-funded by the European Commission, on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment"

International Networking Event (virtual)
on 22 April 2021 hrs 9:00 CET
will focus on the forthcoming co-funded JTC 2021 on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment" 
the event is organized by TUBITAK under the “Turkey in Horizon 2020 Phase II” Technical Assistance Project
in cooperation with TRANSCAN-3

ERA-NET Cofund TRANSCAN-3:
 Sustained collaboration of national and regional programmes in cancer research
is the new project funded by the European Commission under H2020  which started on 1st March 2021 and will last five years (G. A. no. 964264)

A TRANSCAN-2 brochure, highlighting key achievements, is available for download

 

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.

Who's Online

We have 19 guests and no members online